NORAD Promotes the Viability, Migration, and Phenotypic Switch of Human Vascular Smooth Muscle Cells during Aortic Dissection via LIN28B-Mediated TGF-β Promotion and Subsequent Enhanced Glycolysis

• Published in: BioMed research international 2022, Vol.2022, p.5333928-9
• Main Authors: Xia, Shi-bo, Tian, Zhuang-bo, Zhang, Wenbo, Zhang, Hao
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Aorta; Aortic dissection; Aortic Dissection - genetics; Aortic Dissection - metabolism; Cell growth; Cell migration; Cell Movement - genetics; Cell Proliferation; Dissection; DNA Damage; Etiology; Gene expression; Glucose; Glucose - metabolism; Glycolysis; Growth factors; Humans; Metabolism; mRNA; Muscle, Smooth, Vascular - metabolism; Muscles; Myocytes, Smooth Muscle - cytology; RNA, Long Noncoding - genetics; RNA, Untranslated - metabolism; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Smooth muscle; Transforming Growth Factor beta - metabolism; Transforming growth factor-b; Transforming growth factor-b1
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2022/5333928

Glucose metabolism reprogramming is an important reason for the functional remodeling, growth, and migration of vascular smooth muscle cells (VSMCs). It is also an important basis for the occurrence and development of aortic dissection (AD), but the specific regulatory factors are not clear. Noncoding RNA activated by DNA damage (NORAD) is dysfunctional in many diseases, but the role of NORAD in AD etiology is unclear. We first established a vascular remodeling cell model of AD, and the expression of NORAD in VSMCs was significantly increased. Functional experiments showed that inhibition of NORAD could downregulate the proliferation and migration of VSMCs. Meanwhile, silencing NORAD could also inhibit the flux of glycolysis, suggesting that NORAD may aggravate AD by promoting glycolysis. In addition, mechanism studies have shown that NORAD can exert VSMCs-regulating function by recruiting LIN28B to bind to TGF-β mRNA, which subsequently facilitates the expression of TGF-β1 (transforming growth factor β1). The recovery experiment also showed that overexpression of TGF-β could reverse the inhibitory effect of NORAD knockdown on VSMCs in terms of proliferation, migration, and glycolysis. Collectively, these results indicated that the NORAD/LIN28B/TGF-β axis promoted cell proliferation and migration through regulating aerobic glycolysis in VSMCs. Therefore, NORAD may regulate the occurrence of AD by affecting the reprogramming of glucose metabolism, and NORAD can be recognized as a good target for VSMC phenotypic intervention and AD treatment.